We're a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medic
Location: Canada, Ontario, Toronto
Employees: 10001+
Phone: +1 800-268-4623
Total raised: $8M
Founded date: 1974
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.11.2017 | Grant | $8M | - |
Mentions in press and media 13
| Date | Title | Description |
| 05.08.2024 | Vanda Pharmaceuticals: Navigating Challenges and Opportunities in the Biopharmaceutical Landscape | Vanda Pharmaceuticals is at a crossroads. The company recently reported its second-quarter financial results for 2024, revealing a mix of growth and challenges. With revenues of $50.5 million, Vanda saw a 6% increase from the previous quart... |
| 05.08.2024 | Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery | TAIPEI, Aug. 5, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusiv... |
| 05.08.2024 | Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery | TAIPEI, Aug. 5, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusiv... |
| 31.07.2024 | Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results | Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; comme... |
| 03.06.2024 | Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company | Acquisition marks a significant step in Apotex's growth strategy, advancing its position as a preferred Health Partner of Choice in the Americas. TORONTO, June 3, 2024 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"... |
| 08.05.2024 | Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results | Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch expected in Q3 2024 ... |
| 04.10.2022 | SK Capital to Buy Apotex Pharmaceutical | SK Capital Partners, a New York-based private investment firm, acquired Apotex Pharmaceutical Holdings, a Canadian pharmaceutical company. The amount of the deal – closing of which is subject to the satisfaction of customary regulatory cond... |
| 28.09.2022 | SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals | Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement... |
| 03.11.2021 | CloudMD Partners with Apotex Latinoamérica to Drive Expansion of Health Educational Resources Across the Region | VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTC: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a healthcare technology company transforming the delivery of care, is ... |
| 08.02.2012 | Success or withdrawal hang in balance for Shire blood pressure drug | Although the Irish pharmaceutical company, which has U.S. headquarters in the Philadelphia area, no longer manufactures the drug, it agreed to do the additional tests because it holds the new drug application for ProAmatine and did not want... |
Show more